Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca and Cellworks have entered into a Wellcome Trust funded collaboration to develop combination therapies for drug-sensitive and resistant tuberculosis.
Subscribe to our email newsletter
Under the collaboration, Cellworks will leverage its proprietary predictive platform to model drug MDR-TB and rationally identify synergistic combinations with highest possible efficacy and lowest possible toxic burden compared to currently available combinations.
AstraZeneca will then validate the top ten most effective through in vitro assays and using in vivo models.
Cellworks Group India managing director Anand Anandkumar said the drug development project has the potential to save thousands of lives globally.
"Its results may also have positive implications in other infectious disease areas where drug resistance is prevalent," Anandkumar added.
AstraZeneca Infection Innovative Medicines Unit head Manos Perros said, "We believe that new medicines and new combination therapies to treat TB will be delivered through a concerted effort from multiple partners rather than one company’s lab."